Immunovant, Inc. (IMVT)
NASDAQ: IMVT · Real-Time Price · USD
41.82
-0.78 (-1.83%)
At close: Aug 13, 2026, 4:00 PM EDT
42.48
+0.66 (1.58%)
Pre-market: Aug 14, 2026, 8:00 AM EDT
Immunovant Market Cap
Immunovant has a market cap or net worth of $8.64 billion as of August 14, 2026. Its market cap has increased by 225.80% in one year.
Market Cap
8.64B
Enterprise Value
7.84B
1-Year Change
225.80%
Ranking
Category
Stock Price
$41.82
ChartMarket Cap Chart
Since June 21, 2019, Immunovant's market cap has increased from $124.38M to $8.64B, an increase of 6,845.15%. That is a compound annual growth rate of 80.95%.
| Date | Market Cap | % Change |
|---|---|---|
| Aug 13, 2026 | 8.64B | 67.66% |
| Dec 31, 2025 | 5.15B | 41.70% |
| Dec 31, 2024 | 3.64B | -40.34% |
| Dec 29, 2023 | 6.09B | 165.79% |
| Dec 30, 2022 | 2.29B | 134.03% |
| Dec 31, 2021 | 979.80M | -78.33% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Jun 21, 2019 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Apogee Therapeutics | 10.11B |
| Krystal Biotech | 9.68B |
| Protagonist Therapeutics | 9.60B |
| Ionis Pharmaceuticals | 9.21B |
| Kymera Therapeutics | 9.11B |
| Spyre Therapeutics | 9.06B |
| Crinetics Pharmaceuticals | 8.95B |
| Vaxcyte | 8.81B |